Researchers call for new consistent, robust standards for the development of meta-analyses

In light of a huge increase in recent years in the number of meta-analyses published annually about prevention and treatment of heart disease as well as in other fields, the American Heart Association (AHA) published a scientific statement to provide recommendations for physicians and researchers who wish to do meta-analyses, journal editors who publish them, and health care professionals who wish to use them to make decisions about patient care.

Goutham Rao, MD, Chairman of the Department of Family Medicine and Community Health at University Hospitals Cleveland Medical Center and immediate past chair of the AHA's Obesity Committee, is the lead author and chair of the writing group of the statement published on Aug. 9 by the AHA.

Meta-analysis is a type of research design in which researchers identify relevant individual studies, evaluate their quality, and combine results from the individual studies into summary estimates to answer important questions such as what medications are best to prevent stroke in patients with heart rhythm disturbances.

Over the years, as the number of medical research studies have increased - on average about 75 medical studies are published every day, according to Dr. Rao, sometimes with conflicting results on the same subject - experts and the general public cannot keep up with all the information.

Meta-analyses have grown dramatically in number, too. Dr. Rao said the number of meta-analyses published annually has now surpassed the number of clinical trials published annually, now. The fundamental appeal of meta-analysis is the idea of integrating evidence from multiple sources to provide reliable answers to important questions.

In 1991, there were 334 meta-analyses published around the world. Now there are roughly 10,000 meta-analyses published annually, roughly double the number published annually just 5 years ago, according to the AHA statement.

This growing number has caused Dr. Rao and others to question their quality and reliability.

"I proposed to the American Heart Association, about three years ago, that we ought to develop robust standards for how people ought to produce meta-analyses, whether it has to do with heart disease or any other phenomenon," he said.

"What we found in this study is that there are serious problems, there's no consistency in how methods are applied, they're all over the place, and the flaws are pretty obvious," said Dr. Rao.

The AHA statement makes several technical recommendations to improve the quality of meta-analysis, but Dr. Rao said there is no easy solution to the problem.

The statement also makes some over-arching recommendations.

"We say you cannot use any quick tool to evaluate a meta-analysis or the quality of the individual studies which make-up a meta-analysis," said Dr. Rao. "You need to dig deeper, and need to have someone with statistical expertise on your research team if you are going to do a meta-analysis. And, most importantly, you need to make a good case about why you need the meta-analysis...providing a really clear justification for it," he said. "Many meta-analyses are published unnecessary, and serve as a way for junior researchers to get published rather than addressing an important and timely question about patient care."

As for lessons that the general public can glean from this statement, Dr. Rao said, "There are certainly some very high quality meta-analyses out there, but when you hear about a news story which reports results from a meta-analysis, I think a little skepticism is needed. The second thing is there have to be a reasonable set of standards for the methods used for meta-analyses that everybody follows."

"We believe over time that following our standards will lead to better meta-analyses," he said.

Rao G, Lopez-Jimenez F, Boyd J, D'Amico F, Durant NH, Hlatky MA, Howard G, Kirley K, Masi C, Powell-Wiley TM, Solomonides AE, West CP, Wessel J; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; and Stroke Council.
Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association.
Circulation. 2017 Aug 7. doi: 10.1161/CIR.0000000000000523.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...